About

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. We are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2a Cholesterol Efflux Mediator^TM VAR 200. Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications. The total accessible market is over $100 billion.^1-3

IC 100 is a novel inflammasome inhibitor targeting ASC. By targeting ASC, IC 100 inhibits 12 or more types of inflammasomes rather than just one (e.g. NLRP3). It inhibits intracellular ASC to block inflammasome formation and initiation of the inflammatory cascade. It also inhibits intra- and extracellular ASC specks to block systemic perpetuation and spread of damaging inflammation associated with inflammatory diseases.

IC 100 has potential to treat numerous inflammatory conditions including those in the CNS, such as Parkinson’s and Alzheimer’s disease, and those outside the CNS, such as atherosclerosis.  The lead indication for IC 100 is obesity and its associated metabolic complications.

Cholesterol Efflux Mediator^TM VAR 200, 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), was designed to mediate excess cholesterol and lipid removal from podocytes, a component of the kidneys’ filtering system, to slow progression of podocyte injury and reduce spillage of protein into the urine (proteinuria) that can lead to renal failure. A Phase 2a pilot study with VAR 200 in patients with diabetic kidney disease will be initiated in the upcoming weeks.  VAR 200 has potential for treatment of orphan indications, focal segmental glomerulosclerosis (FSGS) and Alport syndrome, in addition to diabetic kidney disease.

ZyVersa’s accomplished leadership team has deep pharmaceutical experience and a successful track record in R&D, commercialization, licensing, M&A, raising capital, and taking companies public. A key focus is assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.